Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LENVAGIST lenvatinib vs placebo in advanced/metastatic GIST after imatinib and sunitinib failure
2018-004332-30Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastrointestinal stromal tumor (GIST) comparing lenvatinib with placebo (2 arms). Primary endpoint: Progression-free survival. Started Jul 2019; status: active.
02
Drugs
lenvatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2018-004332-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004332-30.